| |
|
|
|
|
|
|
TransMessenger™
Comparison |
|
|
Compare TransIT®-mRNA Transfection Kit to TransMessenger™ Reagent:
- More Efficient
- Less Toxic
- Easier to Use
Superior Transfection Performance and Cell Viability
Approximately 80% confluent cells were transfected with a capped and polyadenylated firefly luciferase mRNA using either the TransIT®-mRNA Kit or TransMessenger™ Reagent (Qiagen). Approximately 18 hours post-transfection, cell confluency was determined, cells were harvested and then assayed for luciferase activity. Both TransMessenger sample luciferase activity (gray bars) and cell confluency (black) were scaled relative to the TransIT-mRNA transfected samples (red bars) and presented as a percentage of the TransIT-mRNA samples (set at 100%). In each experiment, the cells transfected with the TransIT-mRNA Transfection Kit were approximately 100% confluent at the time of harvest.
Simple Protocol Saves Time
Advantages of the TransIT®-mRNA Kit
| |
TransIT®-mRNA Kit
|
TransMessenger™
|
| Serum Compatibility |
COMPATIBLE |
Incompatible |
| Cell Wash Prior to Transfection |
No |
Yes |
| Media Change After Complex Addition |
No |
Yes |
| Cell Viability |
High |
Low |
|
Prove It To Yourself
- Request Your FREE TransIT-mRNA Sample Today - MORE
- Check out these publications citing TransIT®-mRNA use:
Gonzalez et. al, (2007) Selection of an Optimal RNA Transfection Reagent and Comparison to Electroporation for the Delivery of Viral RNA. J. Virological Methods. 145:14-21 (Direct comparison to DMRIE-C, TransMessenger™, and electroporation)
Meis and Meis, (2007) The New mScript™ mRNA Production System - Efficient mRNA Transcription, Capping and Tailing for High Yields of Active Protein. EPICENTRE Forum. 14(1):4-5 (Efficient mRNA delivery into HeLa, NIH3T3 and BDCM cell lines) http://www.epibio.com/pdfforum/14_1.pdf
Duan and Jefcoate. (2007) The Predominant cAMP-stimulated 3.5 kb StAR mRNA Contains Specific Sequence Elements in the Extended 3'UTR that Confer High Basal Instability. J. of Mol. Endocrin. 38:159-179 (mRNA transfection followed by mRNA stability measurements)
© 2008 Mirus Bio Corporation. All Rights Reserved.